Ampyra for Optic Neuritis in Multiple Sclerosis

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Multiple Sclerosis, Optic Neuritis

In brief

Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the hypothesis that dalfampridine, when administered to subjects with incomplete visual recovery after optic neuritis from MS, will result in symptomatic improvement in visual function. The study will consist of one screening/baseline visit, one visit during treatment with active drug, and one visit on placebo. After the baseline visit, subjects will be randomly assigned to receive study medication or placebo for the first three weeks, followed by a two week wash-out, and then treatment reallocation for the latter three weeks.

Key facts

Study ID
NCT01337986
Run by
Washington University School of Medicine
People needed
53
Starts
2011-05-01
Expected to finish
2013-12-01
Last updated by the study team
2020-01-30

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.